RalA GTP-loading decreases following mitochondrial depolarization, but does not regulate RalA localization. by Sarah R. Pollock (6597845)

CRISPRi interrogation of the <i>Sox10</i> ECs. by Hongjoo An (21703199)

Coverage of reference gene panel by assay A to E for reference samples. by Lizhi Yu (12476136)

Subjects:

ASM Ca²⁺ signaling receptors expression decreased with age. by Sarah A. Wicher (11204226)

Suppression of STAT6 consistently decreases WT_III encystment. by Joshua A. Kochanowsky (7543169)

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. by Guihua Wang (286390)

Delphinidin alters VEGF-A splicing to increase VEGF-A₁₆₅b and decrease total VEGF-A expression. by Megan Stevens (3964886)

“…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A₁₆₅b relative to total VEGF-A₁₆₅ (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A₁₆₅b before stripping and reprobing with panVEGF-A). …”

The forest plots of the effect of probiotics on the level of IL-10 by ELISA (A) and RT-PCR (B) methods. by Zahra Zangeneh (11772967)

ZfpA overexpression decreases voriconazole efficacy <i>in vitro</i> and during infection. by Taylor J. Schoen (15383519)

Therapeutic effect of TAS5315 on the decrease in bone strength in a mouse CIA model. by Daichi Akasaka (14670684)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

Silencing of TET3 acted to decrease mitochondrial respiration in N2A cells. by Valeria Leon Kropf (17797623)

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”

Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol. by Kaley M. Wilburn (12060476)